Expert Review of Pharmacoeconomics and Outcomes Research This is an RSS file. You can use it to subscribe to this data in your favourite RSS reader or to display this data on your own website or blog.

Unwanted outcomes in cognitive behavior therapy for pathological health anxiety: a systematic review and a secondary original study of two randomized controlled trials
Expert Rev Pharmacoecon Outcomes Res. 2023 Aug 24:1-15. doi: 10.1080/14737167.2023.2250915. Online ahead of print.ABSTRACTINTRODUCTION: Cognitive behavior therapy (CBT) is effective for pathological health anxiety, but little is known about unwanted outcomes.AREAS COVERED: We investigated unwanted outcomes in the form of adverse events, overall symptom deterioration, and dropouts in CBT for pathological health anxiety based on a systematic review of 19 randomized controlled trials (PubMed, PsycInfo, and OATD; last updated 2 June 2023; pooled N = 2188), and then a secondary original study of two randomized controlled trials...
Source: Expert Review of Pharmacoeconomics and Outcomes Research - August 24, 2023 Category: Health Management Authors: Erland Axelsson Erik Hedman-Lagerl öf Source Type: research

Cost-Utility analysis of Multiple Sclerosis rehabilitation in Iran
CONCLUSIONS: The MS multidisciplinary rehabilitation proved to be a cost-effective strategy; however, the results were sensitive to the input values of the model. Increasing the time horizon increased the probability of rehabilitation being cost-effective.PMID:37614049 | DOI:10.1080/14737167.2023.2251689 (Source: Expert Review of Pharmacoeconomics and Outcomes Research)
Source: Expert Review of Pharmacoeconomics and Outcomes Research - August 24, 2023 Category: Health Management Authors: Rajabali Daroudi Mirtaher Mousavi Marzieh Shirazikhah Mehdi Alizadeh Zarei Hamidreza Hendi Faezeh Joghataei Ali Darvishi Source Type: research

Cost-effectiveness of tumor necrosis factor-alpha inhibitors: a systematic review and meta-analysis of cost-utility studies
CONCLUSION: Based on the available evidence during the study period, TNF-a-i is not a cost-effective option for treating RA compared to other DMARDs. However, high heterogeneity and low confidence in GRADE quality assessment preclude the results from being generalizable.PMID:37604704 | DOI:10.1080/14737167.2023.2249610 (Source: Expert Review of Pharmacoeconomics and Outcomes Research)
Source: Expert Review of Pharmacoeconomics and Outcomes Research - August 21, 2023 Category: Health Management Authors: Sajith Kumar Bhavani Shankara Bagepally Source Type: research

Cost-effectiveness analysis of pressure-controlled intermittent coronary sinus occlusion in elective percutaneous coronary intervention
CONCLUSION: PCI+PiCSO proceduremay be considered a cost-effective technology that allows reducing cardiacevents, while improving patients' life expectancy and quality of life.PMID:37589294 | DOI:10.1080/14737167.2023.2249612 (Source: Expert Review of Pharmacoeconomics and Outcomes Research)
Source: Expert Review of Pharmacoeconomics and Outcomes Research - August 17, 2023 Category: Health Management Authors: Carla Rognoni Gaia Segantin Roberto Scarsini Marco Valgimigli Francesco Loizzi Francesco Costa Patrizio Armeni Source Type: research

How can environmental impacts be incorporated in health technology assessment, and how impactful would this be?
Expert Rev Pharmacoecon Outcomes Res. 2023 Aug 14. doi: 10.1080/14737167.2023.2248389. Online ahead of print.NO ABSTRACTPMID:37578859 | DOI:10.1080/14737167.2023.2248389 (Source: Expert Review of Pharmacoeconomics and Outcomes Research)
Source: Expert Review of Pharmacoeconomics and Outcomes Research - August 14, 2023 Category: Health Management Authors: Sarah Catherine Walpole Laura Weeks Koonal Shah Katharine Cresswell Lorena Mesa-Melgarejo Adriana Robayo Felix Greaves Source Type: research

Can artificial intelligence separate the wheat from the chaff in systematic reviews of health economic articles?
CONCLUSIONS: In our case study, all DE articles were identified after screening 7.7% of the sample, allowing for substantial time savings. ASReview likely has the potential to substantially reduce screening time in systematic reviews of health economic articles.PMID:37573521 | DOI:10.1080/14737167.2023.2234639 (Source: Expert Review of Pharmacoeconomics and Outcomes Research)
Source: Expert Review of Pharmacoeconomics and Outcomes Research - August 13, 2023 Category: Health Management Authors: M J Oude Wolcherink X G L V Pouwels S H B van Dijk C J M Doggen H Koffijberg Source Type: research